S

Sage Therapeutics
D

SAGE

5.10000
USD
0.26
(5.37%)
Market Open
Volume
24,131
EPS
-6
Div Yield
-
P/E
-1
Market Cap
311,983,641
OverviewSignalsIdeasNews
Related Instruments
    C
    CLLS
    -0.02000
    (-1.06%)
    1.87000 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    F
    FOLD
    -0.42300
    (-4.19%)
    9.68000 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    R
    RCKT
    -0.810
    (-5.48%)
    13.980 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    More
News

Title: Sage Therapeutics

Sector: Healthcare
Industry: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.